A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.

Rafeletou A, Fathi F, Kiseļova T, Taheri G, Lundberg A

Open source

DOI
10.1038/s41746-026-03254-5
Published
2026 Sep 14
Container
NPJ digital medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41746-026-03254-5,
  title = {A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.},
  author = {Rafeletou A and Fathi F and Kiseļova T and Taheri G and Lundberg A},
  year = {2026},
  journal = {NPJ digital medicine},
  doi = {10.1038/s41746-026-03254-5},
  url = {https://doi.org/10.1038/s41746-026-03254-5}
}

RIS

TY  - JOUR
TI  - A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.
AU  - Rafeletou A
AU  - Fathi F
AU  - Kiseļova T
AU  - Taheri G
AU  - Lundberg A
PY  - 2026
JO  - NPJ digital medicine
DO  - 10.1038/s41746-026-03254-5
UR  - https://doi.org/10.1038/s41746-026-03254-5
ER  - 

APA

A, R., F, F., T, K., G, T., & A, L. (2026). A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.. NPJ digital medicine. https://doi.org/10.1038/s41746-026-03254-5

Source records